OR WAIT 15 SECS
© 2021 MJH Life Sciences™ , Dermatology Times and Multimedia Medical, LLC. All rights reserved.
Chicago - Results from an ongoing phase II clinical trial point out that electrochemotherapy followed by low-dose interleukin-2 (IL-2) (Proleukin) produces a clinical response in a subset of patients with disseminated malignant melanoma, Julie Gehl, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
Related Content:
News